8-K: Varex Imaging Reports Strong Q2, But China Tariffs Prompt Outlook Revision

Varex Imaging Corporation announced a 3% year-over-year revenue increase for Q2 fiscal year 2025, but lowered its short-term outlook due to high tariffs imposed by China.

Summary

• Varex Imaging Corporation reported its Q2 fiscal year 2025 results, showing a 3% increase in revenue to $213 million compared to the same period last year.
• The medical and industrial segments both experienced a 3% year-over-year revenue increase, with medical reaching $154 million and industrial at $59 million.
• GAAP gross margin remained at 36%, while non-GAAP EPS increased to $0.26 from $0.16 in Q2 2024.
• Cash flow from operations was $17 million for the quarter, and the company's cash, cash equivalents, and marketable securities totaled $226 million, excluding $125 million in restricted cash.
• Varex plans to repay its Convertible Notes due in June 2025.
• The company's Q3 fiscal year 2025 revenue guidance is between $180 million and $200 million, with non-GAAP net earnings per diluted share expected to be between -$0.05 and $0.10.
• The reduced outlook is attributed to China-based customers pausing purchases due to high tariffs on U.S. products, with expected sales in China of approximately $10 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the year-over-year revenue growth and improved non-GAAP EPS. However, the reduced outlook due to tariffs and the expected loss in Q3 temper the overall sentiment.

Positives

• Varex achieved year-over-year sales growth across both its medical and industrial segments.
• The company experienced margin expansion, profitability, and cash generation during the quarter.
• Varex plans to reduce its overall debt burden and simplify its capital structure by paying off convertible notes.
• Cash, cash equivalents, and marketable securities increased from $213 million at the end of fiscal year 2024 to $226 million at the end of the second quarter of fiscal year 2025, excluding restricted cash.

Negatives

• China-based customers have paused purchases due to high tariffs imposed by China on U.S. products.
• The company has reduced its outlook for the short term due to the impact of these tariffs.
• The company expects lower revenues for Q3 fiscal year 2025, between $180 million and $200 million, compared to $213 million in Q2.
• Non-GAAP net earnings per diluted share for Q3 fiscal year 2025 is expected to be between -$0.05 and $0.10, a decrease from $0.26 in Q2.

Risks

• The company faces risks associated with changes in import/export regulatory regimes, tariffs, trade wars, and national policies.
• Global, regional, and country-specific economic instability could impact the company's performance.
• Supply chain disruptions could negatively affect the company's ability to meet customer demand.
• The company's performance is subject to limitations imposed by operating and financial restrictions of its debt financing agreements.

Future Outlook

Varex expects Q3 fiscal year 2025 revenues to be between $180 million and $200 million, with non-GAAP net earnings per diluted share between -$0.05 and $0.10, assuming sales in China of approximately $10 million.

Management Comments

• Sunny Sanyal, Chief Executive Officer, stated that demand remained strong in the second quarter, driving year-over-year sales growth across both segments.
• Sunny Sanyal added that higher volumes, improved sales mix, and productivity gains drove margin expansion, profitability, and cash generation in the quarter.
• Sunny Sanyal noted that several China-based customers have paused purchases due to high tariffs imposed by China on U.S. products, causing the company to reduce its outlook for the short term.
• Sam Maheshwari, Chief Financial Officer, stated that paying off convertible notes will reduce the company's overall debt burden and simplify its capital structure.

Industry Context

Varex Imaging operates in the X-ray imaging components market, serving both medical and industrial sectors. The company's performance is influenced by global trade policies, particularly tariffs, and economic conditions in key markets like China. Competitors in this space include companies specializing in X-ray tubes, digital detectors, and imaging software.

Comparison to Industry Standards

• Comparing Varex to industry peers like Canon, Fujifilm, and Siemens Healthineers, Varex's 3% revenue growth is moderate.
• Siemens Healthineers, for example, has shown stronger growth in certain segments due to its broader portfolio of medical devices and solutions.
• Varex's gross margin of 36% is competitive, but companies with higher value-added services may achieve higher margins.
• The impact of tariffs on Varex's China sales highlights the vulnerability of companies with significant exposure to specific geographic markets, a risk that larger, more diversified players may mitigate more effectively.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the reduced outlook.
• Employees may be affected by potential adjustments in production or sales strategies.
• Customers in China may face challenges in accessing Varex's products due to tariffs.
• Suppliers may see adjustments in order volumes based on the company's revised forecasts.

Key Dates

Keywords

Varex Imaging, Financial Results, Q2 2025, Revenue, Earnings, Tariffs, China, Outlook, Medical Imaging, Industrial Imaging